Adherence to meds a pricey problem in the US

Share this article:
Medical costs of patient non-adherence to therapy costs the US $106 billion each year, according to an Express Scripts study, and missed opportunities for use of cheaper meds and delivery systems costs another $57 billion.

Factors in non-adherence include patient perceptions of drug efficacy, drug side effects, refill procrastination, co-payments and forgetfulness. Non-adherence is particularly pronounced among patients with diabetes, the number one driver of higher drug spending due to increased utilization and cost per prescription, according to Express Scripts Drug Trend Report, which noted that non-adherent diabetes patients had both statistically and clinically worse outcomes and that 8% of all diabetes patients had at least one related inpatient admission per year at an average cost of $20,500.

Patient preference for more expensive branded drugs is to blame for $51 billion in waste each year, said the pharmacy benefit management firm. Such “behavioral waste” is especially costly in the cholesterol category, where it represents a 35.5% savings opportunity of $24.78 per member per year, said the study.

The PBM said increased use of generics and lower-cost brands have saved its clients $1.4 billion, with half of that coming through behavior-centric programs in partnership with clients.
Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...